<DOC>
	<DOCNO>NCT02583789</DOCNO>
	<brief_summary>This study represent first trial ass efficacy oral treprostinil therapy patient symptomatic primary secondary Raynaud 's Phenomenon ( RP ) resistant vasodilatory therapy . The study randomize 1:1 UT-15C placebo . The design crossover study subject randomize receive oral treprostinil sustain release tablet match placebo 12 week crossover 12 week . All subject expose 12 week treatment oral UT-15C study .</brief_summary>
	<brief_title>Assess Efficacy Oral Treprostinil Patients With Symptomatic Primary Secondary Raynaud 's Phenomenon</brief_title>
	<detailed_description>A single center double-blinded , placebo-controlled , crossover study assess efficacy oral treprostinil titrate tolerable goal dose 2.0 mg three time per day ( TID ) 20 patient symptomatic primary secondary Raynaud 's Phenomenon resistant vasodilatory therapy . Based pre-screening survey clinic population anticipate least 30 patient per year eligible enrollment . At clinician discretion dose increase tolerate . Eligible subject time sign informed consent diagnosis primary secondary Raynaud 's Phenomenon . Subjects recruit Raynaud 's Clinic , multidisciplinary clinic held Watkins Clinic Shapiro Cardiovascular Center . Subjects assess Screening treatment initiation visit determine eligibility study . This study represent first trial ass efficacy oral treprostinil therapy patient symptomatic primary secondary Raynaud 's phenomenon resistant vasodilatory therapy . Oral treprostinil ( UT-15C ) , synthetic prostacyclin analog inhibits platelet aggregation , induces vasodilation , suppress smooth muscle proliferation . In recent open label study escalate dos oral treprostinil patient systemic sclerosis digital ischemia , oral treprostinil effectively absorb patient scleroderma temporally associate improve cutaneous perfusion temperature . Thus , oral treprostinil may provide new therapeutic option patient refractory secondary Raynaud 's Phenomenon . A recent systematic review demonstrate oral calcium channel blocker , commonly prescribe drug primary RP , minimally effective reduce frequency attack severity . Although Sildenafil show increase digital skin blood flow phase local cool primary RP , role primary RP yet confirm randomize , control trial . To knowledge , study assess use oral prostacyclin therapy disable primary RP , although one multicenter , double-blind , randomize trial oral analog prostacyclin , know beraprost , reduce number RP attack prove beneficial placebo .</detailed_description>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Patients age â‰¥1865 year Active Raynaud 's Phenomenon define patient refractory RP four RP attack per week 2 week inclusion study despite treatment vasodilator least 3 month Patients primary Raynaud 's Phenomenon Patients Raynaud 's secondary connective tissue disease ( include scleroderma ( SSc ) , limited scleroderma ( CREST ) , mixed connective tissue disease ( MCTD ) , primary Sjogren 's syndrome ( SS ) , systemic lupus erythematosus ( SLE ) , diagnosis underlying rheumatic disease base standard criterion Patients stable dose phosphodiesterase inhibitor ( sildenafil , tadalafil vardenafil ) , endothelin antagonist , alpha adrenergic antagonist , calcium channel blocker define 3months change dose allow participate Uncontrolled hypertension , diabetes mellitus , history orthostatic hypotension , acute coronary cerebrovascular event within 3 month , evidence malignancy , history sympathectomy Smoking within 3 month smoke cessation use nicotine product Subjects currently take prostacyclins . Pregnant breast feed consider pregnancy next 4 month Participation trial investigational drug within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>